William Vainchenker

List of Publications by Year
in descending order

157 papers	18,520 citations	13865 67 h-index	12272 133 g-index
164 all docs	164 docs citations	164 times ranked	15384 citing authors

#	Article	IF	Citations
1	Germline ATG2B/GSKIP-containing 14q32 duplication predisposes to early clonal hematopoiesis leading to myeloid neoplasms. Leukemia, 2022, 36, 126-137.	7.2	10
2	Macrophage migration inhibitory factor is overproduced through EGR1 in TET2low resting monocytes. Communications Biology, 2022, 5, 110.	4.4	8
3	An inherited gainâ€ofâ€function risk allele in <scp>EPOR</scp> predisposes to familial <scp>JAK2^{V617F}</scp> myeloproliferative neoplasms. British Journal of Haematology, 2022, 198, 131-136.	2.5	6
4	CCND2 mutations are infrequent events in BCR-ABL1 negative myeloproliferative neoplasm patients. Haematologica, 2021, 106, 863-864.	3.5	5
5	IFN: Jekyll and Hyde. Blood, 2021, 137, 291-293.	1.4	0
6	ATG2B/GSKIP in de novo acute myeloid leukemia (AML): high prevalence of germline predisposition in French West Indies. Leukemia and Lymphoma, 2021, 62, 1770-1773.	1.3	5
7	Role of Rho-GTPases in megakaryopoiesis. Small GTPases, 2021, 12, 399-415.	1.6	5
8	Impact of NFE2 mutations on AML transformation andÂoverall survival in patients with myeloproliferative neoplasms. Blood, 2021, 138, 2142-2148.	1.4	23
9	CALR mutant protein rescues the response of MPL p.R464G variant associated with CAMT to eltrombopag. Blood, 2021, 138, 480-485.	1.4	3
10	Dual role of EZH2 in megakaryocyte differentiation. Blood, 2021, 138, 1603-1614.	1.4	5
11	Induced Pluripotent Stem Cells Enable Disease Modeling and Drug Screening in Calreticulin del52 and ins5 Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e593.	2.7	5
12	PPARÎ³ agonists promote the resolution of myelofibrosis in preclinical models. Journal of Clinical Investigation, 2021, 131, .	8.2	4
13	Functional Consequences of Mutations in Myeloproliferative Neoplasms. HemaSphere, 2021, 5, e578.	2.7	22
14	Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNÎ± in myeloproliferative neoplasms. Blood, 2021, 138, 2231-2243.	1.4	25
15	JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML. Journal of Experimental Medicine, 2021, 218, .	8.5	22
16	The megakaryocyte: a cell with 3 faces as a mythic god?. Blood, 2021, 138, 1199-1200.	1.4	1
17	Lyl-1 regulates primitive macrophages and microglia development. Communications Biology, 2021, 4, 1382.	4.4	8
18	Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia. Haematologica, 2020, 105, 112-123.	3.5	13

#	Article	IF	Citations
19	Megakaryocyte polyploidization: role in platelet production. Platelets, 2020, 31, 707-716.	2.3	20
20	Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development. Leukemia, 2020, 34, 510-521.	7.2	36
21	Immunosuppression by Mutated Calreticulin Released from Malignant Cells. Molecular Cell, 2020, 77, 748-760.e9.	9.7	77
22	Calreticulin del52 and ins5 knock-in mice recapitulate different myeloproliferative phenotypes observed in patients with MPN. Nature Communications, 2020, 11, 4886.	12.8	27
23	Megakaryocytes tame erythropoiesis with TGFÎ²1. Blood, 2020, 136, 1016-1017.	1.4	5
24	Regulation of Platelet Production and Life Span: Role of Bcl-xL and Potential Implications for Human Platelet Diseases. International Journal of Molecular Sciences, 2020, 21, 7591.	4.1	24
25	A p53-JAK-STAT connection involved in myeloproliferative neoplasm pathogenesis and progression to secondary acute myeloid leukemia. Blood Reviews, 2020, 42, 100712.	5.7	16
26	Germline genetic factors in the pathogenesis of myeloproliferative neoplasms. Blood Reviews, 2020, 42, 100710.	5.7	16
27	Different impact of calreticulin mutations on human hematopoiesis in myeloproliferative neoplasms. Oncogene, 2020, 39, 5323-5337.	5.9	12
28	TET2 haploinsufficiency alters reprogramming into induced pluripotent stem cells. Stem Cell Research, 2020, 44, 101755.	0.7	5
29	The Pediatric Acute Leukemia Fusion Oncogene ETO2â€GLIS2 Increases Selfâ€Renewal and Alters Differentiation in a Human Induced Pluripotent Stem Cellsâ€Derived Model. HemaSphere, 2020, 4, e319.	2.7	8
30	A new efficientÂtool for nonâ€invasive diagnosis of fetomaternal platelet antigen incompatibility. British Journal of Haematology, 2020, 190, 787-798.	2.5	6
31	Remodeling of Bone Marrow Hematopoietic Stem Cell Niches Promotes Myeloid Cell Expansion during Premature or Physiological Aging. Cell Stem Cell, 2019, 25, 407-418.e6.	11.1	202
32	The role of the thrombopoietin receptor MPL in myeloproliferative neoplasms: recent findings and potential therapeutic applications. Expert Review of Hematology, 2019, 12, 437-448.	2.2	20
33	Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants. Blood, 2019, 133, 2669-2681.	1.4	74
34	Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells. Blood, 2019, 134, 2383-2387.	1.4	18
35	Disrupted filamin AÍ±IIbÎ²3 interaction induces macrothrombocytopenia by increasing RhoA activity. Blood, 2019, 133, 1778-1788.	1.4	27
36	Rare type 1-like and type 2-like calreticulin mutants induce similar myeloproliferative neoplasms as prevalent type 1 and 2 mutants in mice. Oncogene, 2019, 38, 1651-1660.	5.9	7

#	Article	IF	Citations
37	New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis. Haematologica, 2018, 103, 575-586.	3.5	17
38	Megakaryocyte and polyploidization. Experimental Hematology, 2018, 57, 1-13.	0.4	73
39	JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders. F1000Research, 2018, 7, 82.	1.6	126
40	Myelodysplastic Syndromes: Mechanisms, Diagnosis, and Treatment. , 2018, , 563-563.		0
41	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood, 2018, 132, 4-4.	1.4	32
42	P53 deletion and NrasG12D cooperate for AML. Blood, 2017, 129, 271-273.	1.4	0
43	Acquired TET 2 mutation in one patient with familial platelet disorder with predisposition to AML led to the development of preâ€leukaemic clone resulting in T2â€•ALL and AML â€M0. Journal of Cellular and Molecular Medicine, 2017, 21, 1237-1242.	3.6	10
44	Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood, 2017, 129, 667-679.	1.4	444
45	Critical role of the HDAC6â€“cortactin axis in human megakaryocyte maturation leading to a proplatelet-formation defect. Nature Communications, 2017, 8, 1786.	12.8	35
46	CXCL12/CXCR4 pathway is activated by oncogenic JAK2 in a PI3K-dependent manner. Oncotarget, 2017, 8, 54082-54095.	1.8	25
47	Genetic Alterations of the Thrombopoietin/MPL/JAK2 Axis Impacting Megakaryopoiesis. Frontiers in Endocrinology, 2017, 8, 234.	3.5	39
48	Identification of MPL R102P Mutation in Hereditary Thrombocytosis. Frontiers in Endocrinology, 2017, 8, 235.	3.5	22
49	Downregulation of GATA1 drives impaired hematopoiesis in primary myelofibrosis. Journal of Clinical Investigation, 2017, 127, 1316-1320.	8.2	65
50	Recent advances in understanding myelofibrosis and essential thrombocythemia. F1000Research, 2016, 5, 700.	1.6	39
51	Uncoupling of the Hippo and Rho pathways allows megakaryocytes to escape the tetraploid checkpoint. Haematologica, 2016, 101, 1469-1478.	3.5	18
52	An incomplete trafficking defect to the cell-surface leads to paradoxical thrombocytosis for human and murine MPL P106L. Blood, 2016, 128, 3146-3158.	1.4	16
53	Activity of nonmuscle myosin II isoforms determines localization at the cleavage furrow of megakaryocytes. Blood, 2016, 128, 3137-3145.	1.4	17
54	Eltrombopag, a potent stimulator of megakaryopoiesis. Haematologica, 2016, 101, 1443-1445.	3.5	14

#	Article	IF	Citations
55	Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood, 2016, 127, 333-342.	1.4	149
56	EZH2: a molecular switch of the MPN phenotype. Blood, 2016, 127, 3297-3298.	1.4	2
57	Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood, 2016, 127, 1317-1324.	1.4	220
58	Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood, 2016, 127, 1325-1335.	1.4	261
59	Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature Communications, 2016, 7, 10767.	12.8	177
60	TET2-mediated 5-hydroxymethylcytosine induces genetic instability and mutagenesis. DNA Repair, 2016, 43, 78-88.	2.8	21
61	ATG2B and GSKIP: 2 new genes predisposing to myeloid malignancies. Molecular and Cellular Oncology, 2016, 3, e1094564.	0.7	10
62	P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis. Oncotarget, 2016, 7, 31980-31992.	1.8	38
63	Concise Review: Induced Pluripotent Stem Cells as New Model Systems in Oncology. Stem Cells, 2015, 33, 2887-2892.	3.2	8
64	Level of RUNX1 activity is critical for leukemic predisposition but not for thrombocytopenia. Blood, 2015, 125, 930-940.	1.4	87
65	TET2 loss, a rescue of JAK2V617F HSCs. Blood, 2015, 125, 212-213.	1.4	1
66	A CALR Mutation Preceding BCR-ABL1 in an Atypical Myeloproliferative Neoplasm. New England Journal of Medicine, 2015, 372, 688-690.	27.0	41
67	Germline duplication of ATG2B and GSKIP predisposes to familial myeloid malignancies. Nature Genetics, 2015, 47, 1131-1140.	21.4	107
68	Emergence of a BCR-ABL Translocation in a Patient With the JAK2V617F Mutation: Evidence for Secondary Acquisition of BCR-ABL in the JAK2V617F Clone. Journal of Clinical Oncology, 2014, 32, e76-e79.	1.6	22
69	p19INK4d Controls Hematopoietic Stem Cells in a Cell-Autonomous Manner during Genotoxic Stress and through the Microenvironment during Aging. Stem Cell Reports, 2014, 3, 1085-1102.	4.8	27
70	Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases. Human Mutation, 2014, 35, 15-26.	2.5	101
71	Myeloproliferative Neoplasms: JAK2 Signaling Pathway as a Central Target for Therapy. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, S23-S35.	0.4	23
72	Germ-line JAK2 mutations in the kinase domain are responsible for hereditary thrombocytosis and are resistant to JAK2 and HSP90 inhibitors. Blood, 2014, 123, 1372-1383.	1.4	69

#	Article	IF	Citations
73	Acquired Initiating Mutations in Early Hematopoietic Cells of CLL Patients. Cancer Discovery, 2014, 4, 1088-1101.	9.4	213
74	TET2 Deficiency Inhibits Mesoderm and Hematopoietic Differentiation in Human Embryonic Stem Cells. Stem Cells, 2014, 32, 2084-2097.	3.2	34
75	The formin DIAPH1 (mDia1) regulates megakaryocyte proplatelet formation by remodeling the actin and microtubule cytoskeletons. Blood, 2014, 124, 3967-3977.	1.4	59
76	Defective endomitosis during megakaryopoiesis leads to thrombocytopenia in Fancaâˆ'/âˆ' mice. Blood, 2014, 124, 3613-3623.	1.4	23
77	A new form of macrothrombocytopenia induced by a germ-line mutation in the PRKACG gene. Blood, 2014, 124, 2554-2563.	1.4	69
78	JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation. Blood, 2014, 124, 2104-2115.	1.4	45
79	Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation. Journal of Clinical Investigation, 2014, 124, 580-591.	8.2	163
80	Calr Mutants Retroviral Mouse Models Lead to a Myeloproliferative Neoplasm Mimicking an Essential Thrombocythemia Progressing to a Myelofibrosis. Blood, 2014, 124, 157-157.	1.4	11
81	Clonal architecture of chronic myelomonocytic leukemias. Blood, 2013, 121, 2186-2198.	1.4	232
82	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 2428-2436.	1.6	462
83	Combination treatment for myeloproliferative neoplasms using <scp>JAK</scp> and panâ€class I <scp>PI</scp>3K inhibitors. Journal of Cellular and Molecular Medicine, 2013, 17, 1397-1409.	3.6	50
84	Concomitant germâ€line <scp>RUNX</scp>1 and acquired <scp>ASXL</scp>1 mutations in a Tâ€cell acute lymphoblastic leukemia. European Journal of Haematology, 2013, 91, 277-279.	2.2	25
85	JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNÎ±. Blood, 2013, 122, 1464-1477.	1.4	122
86	Heterozygous and Homozygous JAK2V617F States Modeled by Induced Pluripotent Stem Cells from Myeloproliferative Neoplasm Patients. PLoS ONE, 2013, 8, e74257.	2.5	32
87	RUNX1-induced silencing of non-muscle myosin heavy chain IIB contributes to megakaryocyte polyploidization. Nature Communications, 2012, 3, 717.	12.8	122
88	Presence of a defect in karyokinesis during megakaryocyte endomitosis. Cell Cycle, 2012, 11, 4385-4389.	2.6	21
89	Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes. Blood, 2012, 119, 4625-4635.	1.4	49
90	Dysmegakaryopoiesis of FPD/AML pedigrees with constitutional RUNX1 mutations is linked to myosin II deregulated expression. Blood, 2012, 120, 2708-2718.	1.4	93

#	Article	IF	Citations
91	MYH10 protein expression in platelets as a biomarker of RUNX1 and FLI1 alterations. Blood, 2012, 120, 2719-2722.	1.4	68
92	TET2, a tumor suppressor in hematological disorders. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1825, 173-177.	7.4	16
93	Down-regulation of the RUNX1-target gene NR4A3 contributes to hematopoiesis deregulation in familial platelet disorder/acute myelogenous leukemia. Blood, 2011, 118, 6310-6320.	1.4	53
94	Monocytic cells derived from human embryonic stem cells and fetal liver share common differentiation pathways and homeostatic functions. Blood, 2011, 117, 3065-3075.	1.4	45
95	Thrombocytopenia resulting from mutations in filamin A can be expressed as an isolated syndrome. Blood, 2011, 118, 5928-5937.	1.4	148
96	TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and IsÂa Recurrent Event during Human Lymphomagenesis. Cancer Cell, 2011, 20, 25-38.	16.8	792
97	Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies. Journal of Clinical Oncology, 2011, 29, 573-582.	1.6	272
98	New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 2011, 118, 1723-1735.	1.4	346
99	FLT3-Mediated p38â€“MAPK Activation Participates in the Control of Megakaryopoiesis in Primary Myelofibrosis. Cancer Research, 2011, 71, 2901-2915.	0.9	46
100	Inhibition of TET2-mediated conversion of 5-methylcytosine to 5-hydroxymethylcytosine disturbs erythroid and granulomonocytic differentiation of human hematopoietic progenitors. Blood, 2011, 118, 2551-2555.	1.4	163
101	Orientation-specific signalling by thrombopoietin receptor dimers. EMBO Journal, 2011, 30, 4398-4413.	7.8	83
102	A major role of TGF-Î²1 in the homing capacities of murine hematopoietic stem cell/progenitors. Blood, 2010, 116, 1244-1253.	1.4	34
103	Myeloproliferative neoplasm induced by constitutive expression of JAK2V617F in knock-in mice. Blood, 2010, 116, 783-787.	1.4	148
104	Aurora B is dispensable for megakaryocyte polyploidization, but contributes to the endomitotic process. Blood, 2010, 116, 2345-2355.	1.4	37
105	Two routes to leukemic transformation after a JAK2 mutationâ€“positive myeloproliferative neoplasm. Blood, 2010, 115, 2891-2900.	1.4	269
106	Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood, 2010, 116, 1132-1135.	1.4	121
107	A Senescence-Like Cell-Cycle Arrest Occurs During Megakaryocytic Maturation: Implications for Physiological and Pathological Megakaryocytic Proliferation. PLoS Biology, 2010, 8, e1000476.	5.6	81
108	Induction of myeloproliferative disorder and myelofibrosis by thrombopoietin receptor W515 mutants is mediated by cytosolic tyrosine 112 of the receptor. Blood, 2010, 115, 1037-1048.	1.4	68

#	Article	IF	Citations
109	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica, 2009, 94, 1676-1681.	3.5	234
110	An activating mutation in the CSF3R gene induces a hereditary chronic neutrophilia. Journal of Experimental Medicine, 2009, 206, 1701-1707.	8.5	75
111	Mutation inTET2in Myeloid Cancers. New England Journal of Medicine, 2009, 360, 2289-2301.	27.0	1,614
112	Analysis of the Ten-Eleven Translocation 2 (TET2) gene in familial myeloproliferative neoplasms. Blood, 2009, 114, 1628-1632.	1.4	96
113	Molecular and Genetic Bases of Myeloproliferative Disorders: Questions and Perspectives. Clinical Lymphoma and Myeloma, 2009, 9, S329-S339.	1.4	13
114	Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood, 2009, 114, 1842-1851.	1.4	24
115	A common bipotent progenitor generates the erythroid and megakaryocyte lineages in embryonic stem cellâ€“derived primitive hematopoiesis. Blood, 2009, 114, 1506-1517.	1.4	142
116	MAL/SRF complex is involved in platelet formation and megakaryocyte migration by regulating MYL9 (MLC2) and MMP9. Blood, 2009, 114, 4221-4232.	1.4	77
117	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood, 2009, 114, 3285-3291.	1.4	264
118	The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse model. Journal of Clinical Investigation, 2009, 119, 852-64.	8.2	80
119	JAKs in pathology: Role of Janus kinases in hematopoietic malignancies and immunodeficiencies. Seminars in Cell and Developmental Biology, 2008, 19, 385-393.	5.0	153
120	A nonsynonymous SNP in the ITGB3 gene disrupts the conserved membrane-proximal cytoplasmic salt bridge in the Î±IIbÎ²3 integrin and cosegregates dominantly with abnormal proplatelet formation and macrothrombocytopenia. Blood, 2008, 111, 3407-3414.	1.4	94
121	P19INK4D links endomitotic arrest and megakaryocyte maturation and is regulated by AML-1. Blood, 2008, 111, 4081-4091.	1.4	47
122	JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders. Blood, 2008, 112, 1402-1412.	1.4	159
123	Activating mutations in human acute megakaryoblastic leukemia. Blood, 2008, 112, 4220-4226.	1.4	141
124	The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood, 2008, 112, 2429-2438.	1.4	101
125	Megakaryocyte endomitosis is a failure of late cytokinesis related to defects in the contractile ring and Rho/Rock signaling. Blood, 2008, 112, 3164-3174.	1.4	171
126	Evidence for MPL W515L/K mutations in hematopoietic stem cells in primitive myelofibrosis. Blood, 2007, 110, 3735-3743.	1.4	96

#	Article	IF	Citations
127	Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood, 2007, 109, 71-77.	1.4	154
128	Proplatelet formation is regulated by the Rho/ROCK pathway. Blood, 2007, 109, 4229-4236.	1.4	153
129	Interrelation between polyploidization and megakaryocyte differentiation: a gene profiling approach. Blood, 2007, 109, 3225-3234.	1.4	108
130	The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood, 2007, 110, 1013-1021.	1.4	172
131	Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia. Blood, 2007, 109, 2202-2204.	1.4	114
132	Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood, 2006, 108, 346-352.	1.4	221
133	Reduced retention of radioprotective hematopoietic cells within the bone marrow microenvironment in CXCR4â€"/â€" chimeric mice. Blood, 2006, 107, 2243-2251.	1.4	103
134	An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood, 2006, 107, 1864-1871.	1.4	137
135	Mammalian target of rapamycin (mTOR) regulates both proliferation of megakaryocyte progenitors and late stages of megakaryocyte differentiation. Blood, 2006, 107, 2303-2310.	1.4	84
136	The SCL relative LYL-1 is required for fetal and adult hematopoietic stem cell function and B-cell differentiation. Blood, 2006, 107, 4678-4686.	1.4	75
137	JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood, 2006, 108, 1652-1660.	1.4	406
138	High molecular response rate of polycythemia vera patients treated with pegylated interferon Â-2a. Blood, 2006, 108, 2037-2040.	1.4	240
139	New Insights into the Pathogenesis of JAK2 V617F-Positive Myeloproliferative Disorders and Consequences for the Management of Patients. Seminars in Thrombosis and Hemostasis, 2006, 32, 341-351.	2.7	35
140	Deficiency in the Wiskott-Aldrich protein induces premature proplatelet formation and platelet production in the bone marrow compartment. Blood, 2006, 108, 134-140.	1.4	183
141	Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin. Journal of Immunology, 2006, 176, 6425-6433.	0.8	21
142	RGS16 is a negative regulator of SDF-1â€"CXCR4 signaling in megakaryocytes. Blood, 2005, 106, 2962-2968.	1.4	92
143	A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 2005, 434, 1144-1148.	27.8	3,221
144	JAK1 and Tyk2 Activation by the Homologous Polycythemia Vera JAK2 V617F Mutation. Journal of Biological Chemistry, 2005, 280, 41893-41899.	3.4	151

#	Article	IF	Citations
145	Mechanisms of WASp-mediated hematologic and immunologic disease. Blood, 2004, 104, 3454-3462.	1.4	134
146	Differential regulation of actin stress fiber assembly and proplatelet formation by Î±2Î²1 integrin and GPVI in human megakaryocytes. Blood, 2004, 104, 3117-3125.	1.4	98
147	FLI1 monoallelic expression combined with its hemizygous loss underlies Paris-Trousseau/Jacobsen thrombopenia. Journal of Clinical Investigation, 2004, 114, 77-84.	8.2	145
148	Megakaryocyte polyploidization is associated with a functional gene amplification. Blood, 2003, 101, 541-544.	1.4	75
149	Prominent role of TGF-Î²1 in thrombopoietin-induced myelofibrosis in mice. Blood, 2002, 100, 3495-3503.	1.4	219
150	Distinct effects of thrombopoietin depending on a threshold level of activated Mpl in BaF-3 cells. Journal of Cell Science, 2002, 115, 2329-2337.	2.0	20
151	Asymmetrical segregation of chromosomes with a normal metaphase/anaphase checkpoint in polyploid megakaryocytes. Blood, 2001, 97, 2238-2247.	1.4	48
152	Role of p21Cip1/Waf1 in cell-cycle exit of endomitotic megakaryocytes. Blood, 2001, 98, 3274-3282.	1.4	65
153	Phenotypic and Functional Evidence for the Expression of CXCR4 Receptor During Megakaryocytopoiesis. Blood, 1999, 93, 1511-1523.	1.4	110
154	The Thrombocytopenia of Wiskott Aldrich Syndrome Is Not Related to a Defect in Proplatelet Formation. Blood, 1999, 94, 509-518.	1.4	85
155	Effects of Cytokines on Platelet Production From Blood and Marrow CD34+ Cells. Blood, 1998, 91, 830-843.	1.4	119
156	Endomitosis of Human Megakaryocytes Are Due to Abortive Mitosis. Blood, 1998, 91, 3711-3723.	1.4	161
157	High Thrombopoietin Production by Hematopoietic Cells Induces a Fatal Myeloproliferative Syndrome in Mice. Blood, 1997, 90, 4369-4383.	1.4	235